Individualized 130 hz subthalamic temporal interference stimulation versus medication for motor symptoms in parkinson disease
NCT ID NCT06980935
First seen Sep 09, 2026 ยท Last updated Sep 09, 2026
Summary
The goal of this clinical trial is to evaluate the immediate effects of individualized 130 Hz STN-tTIS(Subthalamic Nucleus - transcranial Temporal Interference Stimulation)on motor symptoms in early-to-mid-stage PD patients during both medication "on" and "off" states. The main questions it aims to answer are: 1. Does the therapeutic effect of STN - tTIS relate to medication? 2. The degree of improvement in motor symptoms of Parkinson's disease patients after STN - tTIS therapy under different medication conditions. Researchers compared the MDS - UPDRS - III improvement scores of tTIS therapy in the "on" and "off" medication phases to see if tTIS could work of independently medication. 1. Visit the clinic once every 1 weeks for therapy and test. 2. Record their symptoms and scores.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Apr 2025
- Finished
-
Sep 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 85 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * MDS diagnosis of primary Parkinson's disease * Hoehn \& Yahr stage \< 3 * Antiparkinsonian drugs remained unchanged in the past four weeks and dosage remained unchanged during the study Exclusion Criteria: * Presence of neurological disorders that may affect the study (e.g., Traumatic brain injury) * History of antipsychotics, antidepressants, or dopamine modulators other than PD drugs * Metal devices in the head or heart (e.g., deep brain stimulators, pacemakers) * Unstable vital signs
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Parkinson disease are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Ruijin Hospital
Shanghai, Shanghai Municipality, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Parkinson's improvement activated by hula understanding (PAHU) - part 2
- Half a million people join quest to decode Parkinson's risk
- Can a diabetes drug slow Parkinson's? a trial puts it to the test
- Horseback therapy may help Parkinson's patients move better
- A psychedelic compound may lift mood in Parkinson's, and a trial puts it to the test
- Mind-Controlled therapy: could brain signals help Parkinson's patients move better?